BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

...leadership at risk while offering little or no substantive national security benefit.” Consortium members are: Abingworth LLP...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Warwick Corporate partners: None Number of employees: 8 Funds raised: £13 million ($17 million) Investors: Abingworth LLP...
BioCentury | Feb 2, 2017
Financial News

Life sciences investor Arix planning L100M listing

...29, 2016) . The firm’s team includes CEO Joseph Anderson, who was a partner at Abingworth LLP...
Items per page:
1 - 3 of 3
BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

...leadership at risk while offering little or no substantive national security benefit.” Consortium members are: Abingworth LLP...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Warwick Corporate partners: None Number of employees: 8 Funds raised: £13 million ($17 million) Investors: Abingworth LLP...
BioCentury | Feb 2, 2017
Financial News

Life sciences investor Arix planning L100M listing

...29, 2016) . The firm’s team includes CEO Joseph Anderson, who was a partner at Abingworth LLP...
Items per page:
1 - 3 of 3